326
Participants
Start Date
May 28, 2004
Primary Completion Date
September 28, 2005
Study Completion Date
September 28, 2005
Placebo
Placebo matched to serostim® as subcutaneous injection.
Serostim® 4 mg
Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
Serostim® 2 mg
Serostim® 2 mg as subcutaneous injection on alternate days.
Weill Medical College of Cornell Universtiy, New York
St. Luke's Roosevelt Hospital, New York
Bronx Women's Interagency HIV Study, The Bronx
Albany Medical College, Albany
1640 Rhode Island Avenue, N.W., Washington D.C.
IDP Research, Annandale
AIDS Research Consortium of Atlanta, Atlanta
3661 South Miami Avenue, Miami
Care Resources, Miami
Office Of Dr Gary Richmond, Fort Lauderdale
Infectious Disease Associates, Sarasota
University of Alabama/Birmingham, Birmingham
Indiana University Infectious Disease Research Clinic, Indianapolis
Hennepin County Medical Center, Minneapolis
Rush University Medical Center, Chicago
Central Texas Clincial research, Austin
University of Colorado Health Sciences Center, Denver
AIDS Alliance, West Hollywood
CARE CLINIC - UCLA Medical Center, Los Angeles
Harbor-UCLA Medical Ctr Research & Education Institute, Torrance
UCSD - AntiViral Research Center, San Diego
1401 N. Palm Canyon, Palm Springs
University of California, San Francisco - Div. of Endocrinology, San Francisco
Kaiser Permanente, San Francisco
Northern California Institute for Research and Education, Inc., San Francisco
Trials Unit Div of Infectious and Immunologic Diseases, Sacramento
Office of Daniel Coulston, M.D., Spokane
Tufts University School of Medicine, Boston
Community Research Initiative of New England, Boston
Community Research Initiative Of New England, Springfield
AIDS Research Program, Vancouver
Lead Sponsor
EMD Serono
INDUSTRY